MarketCap
Arbutus Biopharma Corporation ABUS
$ 5.12
0.1%
Facebook
X
Telegram
Arbutus Biopharma Corporation Interest Expense | ABUS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 459 K | 1.73 M | 2.86 M | 4.01 M | 2.11 M | 226 K | 261 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.01 M | 226 K | 1.66 M |
Quarterly Interest Expense Arbutus Biopharma Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 34 K | 44 K | - | 46 K | 171 K | 198 K | - | 429 K | 482 K | 506 K | - | 762 K | 763 K | 772 K | - | 1.07 M | 1.1 M | 1.04 M | - | 1.1 M | 2 K | 12 K | - | - | - | 104 K | - | 76 K | 68 K | 42 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.1 M | 2 K | 420 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
2.89 B | $ 257.12 | 0.86 % | $ 455 B |  USA |
 |
AbCellera Biologics
ABCL
|
-2.71 M | $ 10.89 | 4.11 % | $ 3.25 B |  Canada |
 |
Evelo Biosciences
EVLO
|
61 K | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
442 K | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.73 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
3.74 M | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
iTeos Therapeutics
ITOS
|
3.11 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
741 K | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-3.52 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
6.91 M | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
98 K | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
1.77 M | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-4.68 M | $ 37.01 | 0.27 % | $ 1.77 T |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
2.37 M | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
Axcella Health
AXLA
|
3.02 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-3 K | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | USA |
 |
Achieve Life Sciences
ACHV
|
-36 K | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
2.3 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
2.42 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
2.7 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | USA |
 |
AC Immune SA
ACIU
|
1.89 M | $ 2.76 | 2.6 % | $ 278 M |  Schweiz |
 |
Cerevel Therapeutics Holdings
CERE
|
10.6 M | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
8.51 M | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | USA |
 |
Adagene
ADAG
|
1.11 M | $ 3.4 | 2.72 % | $ 201 M |  China |
 |
ADC Therapeutics SA
ADCT
|
22.7 M | $ 1.07 | 0.45 % | $ 136 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
165 K | $ 4.9 | 0.08 % | $ 3.28 M | USA |
 |
ADMA Biologics
ADMA
|
-212 K | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
11.8 M | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
72.4 M | $ 6.94 | 0.73 % | $ 206 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.96 M | $ 33.6 | 0.16 % | $ 1.95 B | USA |